Glenmark releases a combination medication for type-2 diabetes called teneligliptin-dapagliflozin

To treat people with type 2 diabetes, Glenmark Pharmaceuticals is the first company to introduce a fixed dose combination of teneligliptin and dapagliflozin. Glenmark’s combi drug for type-2 diabetes to be sold under brand name Zita D.

The combination drug, sold on a doctor’s prescription, contains teneligliptin (20mg) and dapagliflozin (5 mg or 10mg, respectively) and is to be taken once a day to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially those with other comorbidities, the company said..

Sold under the brand name Zita D, the combination drug is priced at ₹14 per tablet (teneligliptin 20mg + dapagliflozin 5mg), and ₹15 per tablet (teneligliptin 20 mg + dapagliflozin 10 mg).

Shopping Cart
Scroll to Top